Cargando…

Tamoxifen for prevention of breast cancer: extended long-term follow-up of the IBIS-I breast cancer prevention trial

BACKGROUND: Four previously published randomised clinical trials have shown that tamoxifen can reduce the risk of breast cancer in healthy women at increased risk of breast cancer in the first 10 years of follow-up. We report the long-term follow-up of the IBIS-I trial, in which the participants and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cuzick, Jack, Sestak, Ivana, Cawthorn, Simon, Hamed, Hisham, Holli, Kaija, Howell, Anthony, Forbes, John F
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lancet Pub. Group 2015
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4772450/ https://www.ncbi.nlm.nih.gov/pubmed/25497694 http://dx.doi.org/10.1016/S1470-2045(14)71171-4

Ejemplares similares

Use of anastrozole for breast cancer prevention (IBIS-II): long-term results of a randomised controlled trial
por: Cuzick, Jack, et al.
Publicado: (2020)

Tamoxifen related side effects and their impact on breast cancer incidence: A retrospective analysis of the randomised IBIS-I trial
por: Hale, Michael J., et al.
Publicado: (2020)

Participant-Reported Symptoms and Their Effect on Long-Term Adherence in the International Breast Cancer Intervention Study I (IBIS I)
por: Smith, Samuel George, et al.
Publicado: (2017)

Relationships between CYP2D6 phenotype, breast cancer and hot flushes in women at high risk of breast cancer receiving prophylactic tamoxifen: results from the IBIS-I trial
por: Sestak, I, et al.
Publicado: (2012)

Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): a double-blind, randomised controlled trial
por: Forbes, John F, et al.
Publicado: (2016)

Impact of preventive therapy on the risk of breast cancer among women with benign breast disease
por: Cuzick, Jack, et al.
Publicado: (2015)

Off-treatment bone mineral density changes in postmenopausal women receiving anastrozole for 5 years: 7-year results from the IBIS-II prevention trial
por: Sestak, Ivana, et al.
Publicado: (2021)

Markers for the identification of late breast cancer recurrence
por: Sestak, Ivana, et al.
Publicado: (2015)

Impact of a Panel of 88 Single Nucleotide Polymorphisms on the Risk of Breast Cancer in High-Risk Women: Results From Two Randomized Tamoxifen Prevention Trials
por: Cuzick, Jack, et al.
Publicado: (2017)

Future possibilities in the prevention of breast cancer: Breast cancer prevention trials
por: Cuzick, Jack
Publicado: (2000)

The impact of body mass index on breast cancer incidence among women at increased risk: an observational study from the International Breast Intervention Studies
por: Smith, Samuel G., et al.
Publicado: (2021)

Validation of the IBIS breast cancer risk evaluator for women with lobular carcinoma in-situ
por: Lo, Louisa Lisa, et al.
Publicado: (2018)

Breast cancer prevention in the developing world
por: Cuzick, Jack
Publicado: (2010)

Preventative therapies for healthy women at high risk of breast cancer
por: Sestak, Ivana
Publicado: (2014)

Comparison of risedronate versus placebo in preventing anastrozole-induced bone loss in women at high risk of developing breast cancer with osteopenia
por: Sestak, Ivana, et al.
Publicado: (2019)

The mechanism of tamoxifen in breast cancer prevention
por: Yu, F, et al.
Publicado: (2001)

Early participant-reported symptoms as predictors of adherence to anastrozole in the International Breast Cancer Intervention Studies II
por: Sestak, I, et al.
Publicado: (2018)

Mammographic density change in a cohort of premenopausal women receiving tamoxifen for breast cancer prevention over 5 years
por: Brentnall, Adam R., et al.
Publicado: (2020)

Prescribing tamoxifen in primary care for the prevention of breast cancer: a national online survey of GPs’ attitudes
por: Smith, Samuel G, et al.
Publicado: (2017)

Improving decision making about clinical trial participation – a randomised controlled trial of a decision aid for women considering participation in the IBIS-II breast cancer prevention trial
por: Juraskova, I, et al.
Publicado: (2014)

Preventing invasive breast cancer using endocrine therapy
por: Thorat, Mangesh A., et al.
Publicado: (2017)

Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data
por: Cuzick, Jack, et al.
Publicado: (2013)

Factors Predicting Late Recurrence for Estrogen Receptor–Positive Breast Cancer
por: Sestak, Ivana, et al.
Publicado: (2013)

Regarding the Use of Tamoxifen Post-Oophorectomy to Prevent Hereditary Breast Cancer
por: Narod, Steven A
Publicado: (2006)

Effect of tamoxifen and radiotherapy in women with locally excised ductal carcinoma in situ: long-term results from the UK/ANZ DCIS trial
por: Cuzick, Jack, et al.
Publicado: (2010)

Extended Adjuvant Tamoxifen for Early Breast Cancer: A Meta-Analysis
por: Al-Mubarak, Mustafa, et al.
Publicado: (2014)

An Update on Tamoxifen and the Chemo-Preventive Potential of Vitamin E in Breast Cancer Management
por: Khallouki, Farid, et al.
Publicado: (2023)

Uptake of tamoxifen in consecutive premenopausal women under surveillance in a high-risk breast cancer clinic
por: Donnelly, L S, et al.
Publicado: (2014)

A pilot trial to evaluate the acute toxicity and feasibility of tamoxifen for prevention of breast cancer.
por: Powles, T. J., et al.
Publicado: (1989)

Barriers to preventive therapy for breast and other major cancers and strategies to improve uptake
por: DeCensi, Andrea, et al.
Publicado: (2015)

Ibis
por: Vargas Vila, José María, 1860-1933
Publicado: (1908)

Effects of cyclin D(1 )gene amplification and protein expression on time to recurrence in postmenopausal breast cancer patients treated with anastrozole or tamoxifen: a TransATAC study
por: Lundgren, Katja, et al.
Publicado: (2012)

Tamoxifen Resistance in Breast Cancer
por: Chang, Minsun
Publicado: (2012)

First do no harm: extending the debate on the provision of preventive tamoxifen
por: Will, B P, et al.
Publicado: (2001)

The future of breast cancer prevention
por: Howell, A, et al.
Publicado: (2005)

Assessing risk for breast cancer
por: Cuzick, Jack
Publicado: (2008)

Integration of Clinical Variables for the Prediction of Late Distant Recurrence in Patients With Estrogen Receptor–Positive Breast Cancer Treated With 5 Years of Endocrine Therapy: CTS5
por: Dowsett, Mitch, et al.
Publicado: (2018)

Metabolic approaches to breast cancer treatment and prevention
por: Howell, Anthony
Publicado: (2007)

Molecular Drivers of Oncotype DX, Prosigna, EndoPredict, and the Breast Cancer Index: A TransATAC Study
por: Buus, Richard, et al.
Publicado: (2021)

Oral low dose and topical tamoxifen for breast cancer prevention: modern approaches for an old drug
por: Lazzeroni, Matteo, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_125b5j2mle43mc6fjkjkc1e1vq